Lutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial

Edmond M. Kwan, Sarah W.S. Ng, Sofie H. Tolmeijer, Louise Emmett, Shahneen Sandhu, James P Buteau, Amir Iravani, Anthony M. Joshua, Roslyn J. Francis, Vinod Vijay Subhash, Sze-Ting Lee, Andrew M. Scott, Andrew Martin, Martin R. Stockler, Gráinne Donnellan, Matti Annala, Cameron Herberts, Ian D. Davis, Michael S. Hofman, Arun Azad, Alexander W. Wyatt, on behalf of the TheraP Investigators and the ANZUP Cancer Trials Group, Tim Akhurst, Ramin Alipour, Dale L. Bailey, Patricia Banks, Alexis Beaulieu, Louise Campbell, Wei Chua, Megan Crumbaker, Nattakorn Dhiantravan, Kate Ford, Craig Gedye, Jeffrey C. Goh, Alex Guminski, Anis Hamid, Mohammad B. Haskali, Rodney J. Hicks, Edward Hsiao, Terry Hung, Ian Kirkwood, Grace Kong, Ailsa Langford, Nicola Jane Lawrence, Jeremy Lewin, Peter Lin, Michael McCarthy, Margaret McJannett, William M. McDonald, Kate Moodie, Declan G. Murphy, Siobhan Ng, Andrew Nguyen, David A. Pattison, David Pook, Izabella Pokorski, Shakher Ramdave, Nisha Rana, Aravind S. Ravi Kumar, Andrew Redfern, Paul Roach, Peter Roselt, Natalie Rutherford, Javad Saghebi, Geoffrey Schembri, Lavinia Spain, Shalini Subramaniam, Thean Hsiang Tan, Sue Ping Thang, Paul Thomas, Ben Tran, John Violet, Roslyn E. Wallace, Andrew Weickhardt, Scott Williams, Sonia Yip, Alison Y. Zhang